Wanbury Gets USFDA Form 483 With Six Observations At Tanuku API Facility

Market snapshot: Wanbury Limited has received a Form 483 with six observations from the USFDA following a Current Good Manufacturing Practices inspection at its Tanuku API manufacturing facility in Andhra Pradesh. The audit was conducted from July 13 to July 17, 2026. The company will submit its responses within the stipulated timeframe.

Data Snapshot

• The USFDA inspection at the Tanuku API site resulted in six observations in Form 483.
• Wanbury's Tanuku facility successfully cleared a quality audit by Australia's Therapeutic Goods Administration on June 10, 2026.
• Wanbury reported a 117% YoY increase in audited net profit to ₹66.1 crore for FY26.

What's Changed

• Transitioned from zero regulatory observations during previous audits (such as the December 2024 ANVISA audit and June 2026 Australian TGA audit) to receiving six observations in the USFDA Form 483 for the Tanuku site.

Key Takeaways

• The USFDA conducted a cGMP audit at Wanbury's Tanuku API facility in Andhra Pradesh from July 13 to July 17, 2026.
• The audit concluded with the issuance of Form 483 containing six compliance observations.
• Wanbury is preparing to submit detailed corrective responses to the regulatory authority within the permitted timeframe.
• The Tanuku site recently cleared quality inspections from Australia's TGA and Brazil's ANVISA with positive compliance status.

SAHI Perspective

The six observations noted at the Tanuku API site mark a brief regulatory bottleneck for Wanbury, which has otherwise demonstrated strong operational and compliance momentum. Given that Tanuku is a major API site serving developed markets and was recently expanded to support anesthetic API exports to Europe, resolving these observations promptly is crucial to avoid any future supply or regulatory escalation.

Market Implications

The stock could experience short-term volatility or downward pressure because USFDA observations require comprehensive corrective actions and can potentially delay new product approvals from the affected facility if not closed satisfactorily.

Trading Signals

Market Bias: Bearish

The USFDA's Form 483 with six observations at the Tanuku facility is a near-term headwind that could trigger profit booking, overshadowing the positive sentiment from the 117% surge in FY26 net profit.

Underweight: Pharmaceuticals

Trigger Factors:

• Details of the six observations and whether they are procedural or critical data integrity issues.
• USFDA's response to Wanbury's CAPA (Corrective and Preventive Action) submission.
• The timeline for resolution and clear status updates of the Tanuku plant.

Time Horizon: Near-term (0-3 months)

Industry Context

Active Pharmaceutical Ingredient manufacturers face strict regulatory scrutiny from the USFDA. Tanuku is one of Wanbury's two primary FDA-approved facilities, supporting key products like Metformin and Sertraline. Maintaining compliance is essential to safeguarding generic drug exports to highly regulated Western markets.

Key Risks to Watch

• Failure to address the USFDA observations adequately could result in the escalation of the Form 483 to a Warning Letter or Import Alert.
• Potential delays in commercializing newly developed APIs or scaling exports from the Tanuku facility.

Recent Developments

In June 2026, Wanbury's Tanuku API site successfully completed a quality inspection by Australia's Therapeutic Goods Administration. In April 2026, the company cleared Korea's MFDS inspection at its Patalganga site with zero observations.

Closing Insight

While six observations introduce short-term compliance hurdles, Wanbury's proactive approach to resolving the findings within the stipulated timeline aligns with its long-term focus on quality assurance and operational scaling.

High Performance Trading with SAHI.